NASDAQ:IMVT

Immunovant Stock Insider Trading

etoro logo Buy IMVT
*Your capital is at risk
$37.62
-0.480 (-1.26%)
At Close: Jun 23, 2026

Immunovant Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 90.46. In total, the insiders bought 26.23M and sold 735.97K IMVT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
90.46
Buy 26.23M shares
Sell 735.97K shares
53% Buy Activity
Moderate Negative Correlation
Sell Signal Low Confidence
May 28, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 90.46.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 18, 2026
Sell
Common Stock
S-Sale
Van Tuyl Christopher
Chief Legal Officer
Officer 2 634
Value: $93.2K
Jun 15, 2026
Buy
Common Stock
M-Exempt
Pande Atul
Director
Director 1 500
Value: $12.6K
Jun 15, 2026
Sell
Common Stock
S-Sale
Pande Atul
Director
Director 1 500
Value: $51.0K
Jun 15, 2026
Buy
Stock Option (right to buy)
M-Exempt
Pande Atul
Director
Director 1 500
Value: $12.6K
May 28, 2026
Buy
Stock Option (right to buy)
M-Exempt
Fromkin Andrew J.
Director
Director 16 260
Value: $239.0K
May 28, 2026
Buy
Stock Option (right to buy)
M-Exempt
Fromkin Andrew J.
Director
Director 71 492
Value: $567.6K
May 28, 2026
Buy
Stock Option (right to buy)
M-Exempt
Fromkin Andrew J.
Director
Director 31 668
Value: $158.0K
May 28, 2026
Buy
Common Stock
M-Exempt
Fromkin Andrew J.
Director
Director 31 668
Value: $158.0K
May 28, 2026
Buy
Common Stock
M-Exempt
Fromkin Andrew J.
Director
Director 71 492
Value: $567.6K
May 28, 2026
Buy
Common Stock
M-Exempt
Fromkin Andrew J.
Director
Director 16 260
Value: $239.0K
May 28, 2026
Sell
Common Stock
S-Sale
Fromkin Andrew J.
Director
Director 11 483
Value: $374.8K
May 28, 2026
Buy
Common Stock
M-Exempt
Fromkin Andrew J.
Director
Director 77 181
Value: $650.6K
May 28, 2026
Sell
Common Stock
S-Sale
Fromkin Andrew J.
Director
Director 210 468
Value: $7.06M
May 28, 2026
Buy
Stock Option (right to buy)
M-Exempt
Fromkin Andrew J.
Director
Director 77 181
Value: $650.6K
May 20, 2026
Sell
Common Stock
S-Sale
Gloria Melanie
Chief Operating Officer
C-Suite Officer 1 698
Value: $55.9K
May 20, 2026
Sell
Common Stock
S-Sale
Gloria Melanie
Chief Operating Officer
C-Suite Officer 249
Value: $8K
May 20, 2026
Sell
Common Stock
S-Sale
Gloria Melanie
Chief Operating Officer
C-Suite Officer 1 168
Value: $37.6K
May 20, 2026
Sell
Common Stock
S-Sale
Pande Atul
Director
Director 6 000
Value: $192.0K
May 20, 2026
Buy
Common Stock
M-Exempt
Pande Atul
Director
Director 6 000
Value: $50.6K
May 20, 2026
Buy
Stock Option (right to buy)
M-Exempt
Pande Atul
Director
Director 6 000
Value: $50.6K
May 01, 2026
Sell
Common Stock
S-Sale
Susman Robert Graham
Director
Director 2 502
Value: $68.0K
Apr 23, 2026
Sell
Common Stock
S-Sale
Stout Jay S
Chief Technology Officer
Officer 2 754
Value: $81.6K
Apr 23, 2026
Sell
Common Stock
S-Sale
Girao Tiago
Chief Financial Officer
C-Suite Officer 25 760
Value: $763.0K
Apr 08, 2026
Sell
Common Stock
S-Sale
Stout Jay S
Chief Technology Officer
Officer 1 518
Value: $37.7K
Apr 08, 2026
Sell
Common Stock
S-Sale
Stout Jay S
Chief Technology Officer
Officer 8 614
Value: $213.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT IMMUNOVANT, INC.
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
20.46% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
OSW
$24.00
17.08% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE